All HHS Contracts — June 17, 2026
The sole HHS contract analyzed, a $126.4M cost-plus-fixed-fee delivery order awarded to Leidos Holdings, Inc. by the NIH National Cancer Institute, represents a stable, low-risk civilian revenue stream for the company through August 2024. The contract, won under full-and-open competition, reinforces Leidos' entrenched position in federal life sciences R&D facility management, but its fixed end date and lack of options limit upside. With $74.2M already outlayed, approximately $52.2M remains in obligated funding, providing near-term visibility. The key risk is the absence of a follow-on award or extension, which could create a revenue gap for Leidos' biomedical research segment. No defense-related contracts were identified in this period, underscoring a purely civilian healthcare R&D theme.